Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices with more than 15,000 employees and revenue of $3.5 billion in 2003. For 25 years, Boston Scientific has advanced the practice of less-invasive medicine by providing a broad and deep portfolio of innovative products, technologies and services across a wide range of medical specialties.

Some highlights of their recent innovations include the TAXUS™ Express2™ paclitaxel-eluting coronary stent system, a revolutionary new treatment for coronary artery disease; the Enteryx® technology, an endoscopic, injectable new treatment for the symptoms of gastroesophogeal reflux disease (GERD); Matrix™ Detachable Coils, a next-generation aneurysm therapy designed to prevent aneurysms from rupturing and to promote healing; the Contour SE™ embolic agent for treating uterine fibroids through uterine fibroid embolization (a less-invasive alternative to surgery); and the Hydro ThermAblator® Endometrial Ablation System for the treatment of excessive menstrual bleeding due to benign causes.

Through organic research and development, investments and acquisitions, Boston Scientific continues to develop a broad range of new products and technologies to help physicians improve patients’ lives.